ES-ERCPNCT07702240
Esketamine Versus Sufentanil for Sedation in Patients Undergoing ERCP
At risk: Primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Phase changed: Not applicable → Phase 4 Show 6 more changesShow less
- Primary endpoint(s) modified
- Start date: Jul 10, 2026 to Nov 11, 2026
- Eligibility criteria expanded, about 163 words
- Enrollment target: 530 to 580
- Secondary endpoint revised
- Study description expanded, about 36 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (1)
Arms and interventions
Participants receive intravenous esketamine in combination with propofol for procedural sedation during ERCP. Esketamine is administered as an adjunct analgesic during induction of sedation, while propofol is continuously infused and titrated according to clinical sedation requirements.
Participants receive intravenous sufentanil in combination with propofol for procedural sedation during ERCP. Sufentanil is administered as an adjunct analgesic during induction of sedation, while propofol is continuously infused and titrated according to clinical sedation requirements.
Drugs: Esketamine, Sufentanil